Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.33 |
| ▸ | HTR3B | O95264 | 2/20 | 0.33 |
| ▸ | HTR3A | P46098 | 2/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL767180 | 0.83 | TSHR (0.42) | KDM4EALDH1A1HSD17B10TP53NPC1 | |
| SCHEMBL7574859 | 0.81 | FSCN1 (0.35) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL6204339 | 0.80 | ALDH1A1 (0.49) | KDM4EALDH1A1GAALMNANPC1 | |
| SCHEMBL27648859 | 0.78 | ALDH1A1 (0.33) | ALDH1A1GAAHPGDTP53TSHR | |
| SCHEMBL1867402 | 0.76 | ABL1 (0.46) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL10388530 | 0.76 | ALOX15 (0.41) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL7584139 | 0.76 | HPGD (0.40) | KDM4EALDH1A1GAAHPGDNPC1 | |
| SCHEMBL10388340 | 0.76 | ALDH1A1 (0.38) | KDM4EALDH1A1GAALMNATSHR | |
| SCHEMBL4628895 | 0.76 | PARP1 (0.43) | PARP1KDM4EALDH1A1HSD17B10TSHR | |
| SCHEMBL5217422 | 0.76 | PARP1 (0.43) | PARP1KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318006-B1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | NIVALIS THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | claimed |
| US-9138427-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2015-09-22 | — | — | US | claimed |
| US-20140194425-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | claimed |
| JP-2012500216-A | — | — | 2012-01-05 | — | — | JP | claimed |
| US-20110144110-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, LLC (US) | 2011-06-16 | — | — | US | claimed |
| EP-2318006-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 Pharmaceuticals, LLC (US) | 2011-05-11 | — | — | EP | claimed |
| WO-2010019903-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | claimed |
| US-9814700-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170049750-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | LAUREL THERAPEUTICS LTD. (CN) | 2017-02-23 | — | — | US | disclosed |
| US-9498466-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| EP-2318006-B1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | NIVALIS THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-3069721-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | Nivalis Therapeutics, Inc. (US) | 2016-09-21 | — | — | EP | disclosed |
| EP-2315591-B1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | NIVALIS THERAPEUTICS INC (US) | 2016-03-16 | — | — | EP | disclosed |
| US-8673961-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | N30 PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20110144180-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, LLC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144110-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, LLC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2318006-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 Pharmaceuticals, LLC (US) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010019903-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
| EP-1848713-A2 | AMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006053778-A2 | AMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049750-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | PARP1 1701/4885KDM4E 1572/4885ALDH1A1 449/4885 |
| US-20140194425-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | PARP1 1701/4885KDM4E 1572/4885ALDH1A1 449/4885 |
| US-20110144180-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | PARP1 1701/4885KDM4E 1572/4885ALDH1A1 449/4885 |
| US-20110144110-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | PARP1 1701/4885KDM4E 1572/4885ALDH1A1 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.